KX-A141

KX-A141 is a small molecule Janus kinase 3 (JAK3) inhibitor being developed by Kintor Pharmaceutical (through its subsidiary Suzhou Koshine Biomedica) for the treatment of alopecia areata. Unlike androgenetic alopecia, which is driven by hormonal factors, alopecia areata is an autoimmune condition characterized by the immune system attacking hair follicles. KX-A141 is designed as a topical treatment to modulate the JAK/STAT signaling pathway, specifically targeting JAK3 to inhibit the inflammatory response and promote hair regrowth while minimizing the systemic side effects often associated with oral JAK inhibitors. The drug has received Investigational New Drug (IND) clearance to proceed with clinical trials in China.